Most Likely Diagnosis: Mixed Connective Tissue Disease (MCTD) with Inflammatory Myopathy
Based on your positive anti-RNP antibodies (4.7, significantly elevated), proximal muscle weakness, mildly elevated CK, positive ANA, and constellation of systemic symptoms, you most likely have Mixed Connective Tissue Disease with an inflammatory myopathy component. 1
Why This Diagnosis Fits Your Presentation
Key Diagnostic Features Present:
Anti-RNP Antibodies (4.7) - This is the hallmark finding. Anti-U1-RNP antibodies define MCTD and are present in myositis patients with a distinct clinical phenotype 1. Your level is significantly elevated above the normal range of 0-0.9.
Muscle Involvement:
- Your proximal muscle weakness in hips, legs, shoulders, arms, and wrists matches the typical pattern seen in anti-RNP-positive myositis 1
- The mildly elevated CK (371, just above 366 upper limit) is consistent - anti-RNP myositis often has modest CK elevations rather than dramatic ones
- Muscle weakness developed gradually over 3 months, which fits the typical presentation 1
- Pain that improves with Tylenol suggests an inflammatory component
Systemic Features:
- Your GERD could represent esophageal dysmotility, which occurs in 60% of anti-RNP-positive patients 1
- The fasciculations/twitching you describe (legs, elbows, shoulders, toes) may represent muscle irritability from inflammation
- Insomnia and early morning awakening can be part of the systemic inflammatory response
Laboratory Pattern:
- ANA 1:80 positive (expected with anti-RNP)
- ESR of 2 is notably LOW - this is actually characteristic of MCTD, which often has normal inflammatory markers despite active disease 1
- hs-CRP of 3.3 shows mild inflammation
- Normal vitamin D, B12, folate rules out nutritional myopathies
What Makes This MCTD Rather Than Other Conditions
Not Dermatomyositis: You lack the characteristic skin findings (heliotrope rash, Gottron's papules/sign) that would score points on classification criteria 2. Anti-RNP patients can develop DM-like skin features in 60% of cases, but you haven't described these 1.
Not Pure Polymyositis: The anti-RNP antibody defines a distinct subset. Anti-RNP-positive myositis patients are typically younger (median ~37 years) and have unique extramuscular features 1.
Not Statin Myopathy: You're not on statins, and the pattern doesn't fit.
Not Hypothyroid Myopathy: Your thyroid function is normal (implied by normal metabolic workup).
Critical Next Steps for Your Rheumatology Visit
Essential Additional Testing Needed:
Anti-Ro52 antibodies - 25-40% of anti-RNP patients with pericarditis or glomerulonephritis have coexisting anti-Ro52 1. This matters because:
- If positive, you need cardiac evaluation (echocardiogram) to screen for pericarditis
- Urinalysis to check for glomerulonephritis
Troponin and ECG - To evaluate for cardiac involvement, which can occur in inflammatory myopathies 3
Aldolase level - Another muscle enzyme that may be elevated when CK is only mildly elevated 2
Chest imaging or pulmonary function tests - 45% of anti-RNP-positive patients develop interstitial lung disease 1. Your elevated homocysteine (21.6) and slightly elevated creatinine (1.31) warrant attention, but ILD screening is critical.
EMG and/or muscle MRI - To document the pattern and severity of muscle involvement 3. Four of seven anti-RNP patients in one study had necrotizing muscle biopsies 1, so tissue diagnosis may ultimately be needed.
What Your Rheumatologist Will Likely Do:
Confirm the diagnosis by correlating your anti-RNP positivity with clinical features. The combination of:
- Proximal muscle weakness
- Elevated CK (even mildly)
- Anti-RNP antibodies
- Systemic symptoms
...makes MCTD with myositis highly likely.
Screen for extramuscular involvement:
- Joint examination (arthritis occurs in 60% of anti-RNP patients) 1
- Lung assessment (ILD in 45%) 1
- Cardiac evaluation if anti-Ro52 positive
- Renal function monitoring
Treatment Implications
Good news: Anti-RNP-positive myositis patients in the literature had no cancer-associated myositis and no deaths during study periods 1. This distinguishes MCTD from dermatomyositis, where malignancy screening is critical.
Expected treatment approach:
- Corticosteroids (prednisone 0.5-1 mg/kg) are first-line for inflammatory myopathy with elevated CK and weakness 3
- Steroid-sparing agents (methotrexate, azathioprine, or mycophenolate) are often added early in MCTD because prolonged treatment is typically needed
- Physical therapy to maintain muscle strength during treatment
Important Caveats
Your elevated homocysteine (21.6) needs separate attention - this increases cardiovascular risk and may require folate supplementation or B-vitamin optimization, even though your B12 and folate levels tested normal.
The slightly elevated creatinine (1.31) should be monitored, especially before starting immunosuppressive medications. Ensure your rheumatologist knows about this.
Your insomnia may improve once the underlying inflammatory condition is treated, but may also require specific sleep hygiene interventions 4. The early morning awakening pattern can be seen with inflammatory conditions.
The fasciculations/twitching should be distinguished from true weakness. Your brain MRI tomorrow will help rule out neurologic causes, but these symptoms are likely related to muscle inflammation and irritability rather than a primary neurologic disorder.
Bottom Line
You have a treatable inflammatory muscle disease associated with anti-RNP antibodies, most consistent with Mixed Connective Tissue Disease. The rheumatology evaluation will confirm this and initiate appropriate immunosuppressive therapy. With treatment, most patients experience significant improvement in muscle strength and systemic symptoms. The key is early recognition and treatment to prevent progression and screen for the extramuscular complications that can occur in 40-60% of anti-RNP-positive patients 1.